ArticleInternational journal of molecular sciences2017
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review.Frontiers in pharmacology · 2024Pooled it
- Alternative Treatment of the Resistant-to-Treatment Tourette Syndrome-A Systematic Review.Journal of clinical medicine · 2026Review
- Long-term use of cannabis-based medicines in two children with Tourette syndrome: a case report.Frontiers in psychiatry · 2025Article
- Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.Pharmacopsychiatry · 2024Review
- Effectiveness of speech therapy in treating vocal blocking tics in children with Tourette syndrome: Two case reports.Clinical child psychology and psychiatry · 2024Article
- The Clinical Characterization of Blocking Tics in Patients With Tourette Syndrome.Journal of movement disorders · 2023Article
- Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders.International journal of environmental research and public health · 2023Review
- Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study.Behavioural neurology · 2022Article
- Cannabis Improves Stuttering: Case Report and Interview with the Patient.Cannabis and cannabinoid research · 2021Article
- Cognitive Tic-Like Phenomena in Gilles de la Tourette Syndrome.Journal of clinical medicine · 2021Article
- Blocking Tics in Gilles de la Tourette Syndrome.Frontiers in neurology · 2021Article
- Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray.Tremor and other hyperkinetic movements (New York, N.Y.) · 2021Article
- Association of a Variant ofFrontiers in genetics · 2020Article
- Cannabis Improves Obsessive-Compulsive Disorder-Case Report and Review of the Literature.Frontiers in psychiatry · 2020Article
- Review
- Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey.Cannabis and cannabinoid research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 × 0.1 g cannabis daily. Case 2: a 16-year old patient initially received dronabinol at a maximum dose of 22.4-33.6 mg daily. Both treatments provided significant symptom improvement of vocal blocking tics as well as of comorbid conditions and were well tolerated. Thus, cannabis-based medicine appears to be effective in treatment-resistant TS patients with vocal blocking tics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.